Trodelvy Offers Benefits for Hormone Receptor-Positive Breast Cancer

At the European Society for Medical Oncology Congress 2022, Dr. Rugo presented results from the TROPiCS-02 trial, which was looking to see if the targeted therapy Trodelvy could offer more benefits for people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer than chemotherapy. Currently, Trodelvy is approved to treat previously-treated, metastatic triple-negative breast cancer. Listen to the episode to hear Dr. Rugo explain: the type of medicine Trodelvy is and how it works the results showing people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer lived longer when they received Trodelvy compared to chemotherapy how the results from TROPiCS-02 fit into current treatment options

Om Podcasten

Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.